Ward P Daniel, Heth Jason A, Thompson B Gregory, Marentette Lawrence J
Department of Otolaryngology, University of Michigan, Ann Arbor, Michigan.
Skull Base. 2009 Mar;19(2):133-40. doi: 10.1055/s-0028-1096195.
Analysis of outcomes of a cohort of patients with esthesioneuroblastoma.
Retrospective cohort analysis.
PATIENTS presenting with esthesioneuroblastoma from 1994 to 2006 in a tertiary care academic medical center.
Fifteen consecutive patients diagnosed as having esthesioneuroblastoma were treated during this time period using a subcranial resection. The mean follow-up is 75 months (range, 2 to 240 mos).
The overall survival was 100% and the overall disease-free survival was 49% and 24% at 5 and 15 years, respectively. PATIENTS treated with radiation therapy following surgical resection had a 5- and 15-year disease-free survival of 83.3% compared with a 5- and 15-year disease-free survival of 26.7% and 0%, respectively, for patients whose initial treatment was surgery alone. The mean time to recurrence was 82.1 months. None of the patients had a decrease in Karnofsky Performance Score following subcranial resection.
PATIENTS with esthesioneuroblastoma whose initial treatment consists of surgical resection followed by radiation therapy have a longer disease-free survival than patients treated with surgery alone. However, initial treatment modality did not have an effect on survival. Long-term, close follow-up is necessary to identify recurrences, which can be treated with a high degree of success.
分析一组嗅神经母细胞瘤患者的治疗结果。
回顾性队列分析。
1994年至2006年在一家三级医疗学术医学中心就诊的嗅神经母细胞瘤患者。
在此期间，连续15例被诊断为嗅神经母细胞瘤的患者接受了颅下切除术治疗。平均随访时间为75个月（范围为2至240个月）。
总生存率为100%，5年和15年的无病生存率分别为49%和24%。手术切除后接受放射治疗的患者5年和15年无病生存率分别为83.3%，而初始治疗仅为手术的患者5年和15年无病生存率分别为26.7%和0%。复发的平均时间为82.1个月。颅下切除术后，所有患者的卡氏功能状态评分均未下降。
初始治疗包括手术切除后放疗的嗅神经母细胞瘤患者比单纯手术治疗的患者无病生存期更长。然而，初始治疗方式对生存率没有影响。需要长期密切随访以发现复发情况，复发可以得到高度成功的治疗。
